EN
IT
FERTILADVANCE Aneuploidy Risk: a new genetic test to identify predisposition to producing embryos with aneuploidies
Dear Customer,
we are pleased to introduce FERTILADVANCE Aneuploidy Risk, an innovative genetic test designed to identify an individual predisposition to producing embryos with chromosomal aneuploidies.
In the management of infertile couples, chromosomal aneuploidies represent one of the most complex clinical challenges: a significant cause of implantation failure, recurrent pregnancy loss and— in a smaller but clinically relevant proportion of cases—ongoing pregnancies affected by constitutional chromosomal abnormalities.
In these cases, pathogenic variants in genes involved in:
📍chromatid cohesion and meiotic recombination/crossing-over (key determinants of non-disjunction risk),
📍segregation and checkpoint control (relevant in both meiosis and mitosis),
📍centrosome function and spindle dynamics (relevant to early mitotic errors and complex/mosaic patterns),
may represent predisposing factors associated with an increased likelihood of aneuploidies of meiotic and/or mitotic origin.
To support the clinical assessment of these complex scenarios, Genomica presents FERTILADVANCE Aneuploidy Risk, an advanced genetic test designed to identify an individual predisposition to producing embryos with chromosomal aneuploidies.
The test is based on the analysis of 13 genes, selected according to evidence available in the scientific literature, and associated with an increased risk of:
📍aneuploidies of meiotic origin (alterations in mechanisms of recombination, cohesion and segregation);
📍post-zygotic mitotic errors (mosaicism, complex aneuploidies).
FERTILADVANCE Aneuploidy Risk is not intended to “diagnose” an aneuploidy; rather, it is a tool for individual genetic risk stratification, designed to complement — not replace — the overall clinical assessment.
The test is particularly indicated in the following scenarios:
📍repeated ART/IVF cycles with a high proportion of aneuploid embryos, especially if unexpected in relation to maternal age or the overall clinical picture;
📍repeated implantation failure or recurrent pregnancy loss with suspected chromosomal contribution;
📍a previous pregnancy or conception with documented chromosomal aneuploidy;
📍preconception or pre-IVF assessment to evaluate possible genetic contributors to risk;
📍PGT-A patterns suggestive of mitotic errors (“chaotic” profiles, suspected tripolarity) or meiotic errors (recurrent aneuploidies consistent with non-disjunction).
FERTILADVANCE Aneuploidy Risk complements the tools already available in order to:
📍enrich reproductive genetic counseling with elements of individualized stratification;
📍provide a more informed interpretive key in complex clinical scenarios (e.g., repeated implantation failure, recurrent pregnancy loss, a higher-than-expected proportion of aneuploid embryos);
📍more precisely contextualize the results of previous investigations (e.g., PGT-A patterns suggestive of meiotic or mitotic errors).
Download FERTILADVANCE Aneuploidy Risk
informational brochure by clicking on the image above
For more information about FERTILADVANCE Aneuploidy Risk, please visit the monothematic website or contact our team of geneticists. Our Scientific & Commercial Representative is available for an in-depth meeting and to jointly assess how to integrate the test into your clinical practice. If you would like to receive a collaboration proposal or be connected with our Scientific & Commercial Representative, please write to us:
Contact Genomica
We look forward to sharing the most advanced and innovative diagnostic solutions in the field of genetics.
GENOMICA srl
Marketing & Communication Department
we are pleased to introduce FERTILADVANCE Aneuploidy Risk, an innovative genetic test designed to identify an individual predisposition to producing embryos with chromosomal aneuploidies.
Why talk about aneuploidies
In the management of infertile couples, chromosomal aneuploidies represent one of the most complex clinical challenges: a significant cause of implantation failure, recurrent pregnancy loss and— in a smaller but clinically relevant proportion of cases—ongoing pregnancies affected by constitutional chromosomal abnormalities.
In these cases, pathogenic variants in genes involved in:
📍chromatid cohesion and meiotic recombination/crossing-over (key determinants of non-disjunction risk),
📍segregation and checkpoint control (relevant in both meiosis and mitosis),
📍centrosome function and spindle dynamics (relevant to early mitotic errors and complex/mosaic patterns),
may represent predisposing factors associated with an increased likelihood of aneuploidies of meiotic and/or mitotic origin.
FERTILADVANCE Aneuploidy Risk: risk stratification becomes personalized
To support the clinical assessment of these complex scenarios, Genomica presents FERTILADVANCE Aneuploidy Risk, an advanced genetic test designed to identify an individual predisposition to producing embryos with chromosomal aneuploidies.
The test is based on the analysis of 13 genes, selected according to evidence available in the scientific literature, and associated with an increased risk of:
📍aneuploidies of meiotic origin (alterations in mechanisms of recombination, cohesion and segregation);
📍post-zygotic mitotic errors (mosaicism, complex aneuploidies).
FERTILADVANCE Aneuploidy Risk is not intended to “diagnose” an aneuploidy; rather, it is a tool for individual genetic risk stratification, designed to complement — not replace — the overall clinical assessment.
When can it be useful in clinical practice?
The test is particularly indicated in the following scenarios:
📍repeated ART/IVF cycles with a high proportion of aneuploid embryos, especially if unexpected in relation to maternal age or the overall clinical picture;
📍repeated implantation failure or recurrent pregnancy loss with suspected chromosomal contribution;
📍a previous pregnancy or conception with documented chromosomal aneuploidy;
📍preconception or pre-IVF assessment to evaluate possible genetic contributors to risk;
📍PGT-A patterns suggestive of mitotic errors (“chaotic” profiles, suspected tripolarity) or meiotic errors (recurrent aneuploidies consistent with non-disjunction).
How to integrate the test into the patient pathway
FERTILADVANCE Aneuploidy Risk complements the tools already available in order to:
📍enrich reproductive genetic counseling with elements of individualized stratification;
📍provide a more informed interpretive key in complex clinical scenarios (e.g., repeated implantation failure, recurrent pregnancy loss, a higher-than-expected proportion of aneuploid embryos);
📍more precisely contextualize the results of previous investigations (e.g., PGT-A patterns suggestive of meiotic or mitotic errors).
Further information and contacts
Download FERTILADVANCE Aneuploidy Risk
informational brochure by clicking on the image above
For more information about FERTILADVANCE Aneuploidy Risk, please visit the monothematic website or contact our team of geneticists. Our Scientific & Commercial Representative is available for an in-depth meeting and to jointly assess how to integrate the test into your clinical practice. If you would like to receive a collaboration proposal or be connected with our Scientific & Commercial Representative, please write to us:
Contact Genomica
We look forward to sharing the most advanced and innovative diagnostic solutions in the field of genetics.
GENOMICA srl
Marketing & Communication Department